Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Vivera Pharmaceuticals, Inc. v. Gannett Co., Inc, et al
Case Number:
2:20-cv-05838
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 31, 2020
Gannett Escapes $500M COVID-19 Story Libel Suit, For Now
Vivera Pharmaceuticals Inc. dismissed its federal defamation lawsuit Friday against Gannett, several executives and four USA Today reporters alleging it has suffered $500 million in damages because of a story that criticized its COVID-19 antibody tests, saying it has plans to refile its claims in state court.
-
July 01, 2020
Gannett Hit With $500M Libel Suit Over Antibody Test Story
Vivera Pharmaceuticals Inc. has hit Gannett, several executives and four USA Today reporters with a defamation lawsuit in California federal court, alleging it has suffered over $500 million in damages because of a story that criticized its COVID-19 antibody tests and detailed its CEO's past troubles with the U.S. Food and Drug Administration.